News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Looks for New Heart Drug Approval by Next May



9/18/2013 7:09:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

U.S. regulators have accepted an experimental fish oil-based heart drug from AstraZeneca for review and will make a decision on whether to approve it by next May. Epanova, for treating people with very high levels of fatty triglycerides in their blood, was developed by Omthera Pharmaceuticals, which AstraZeneca acquired earlier this year. AstraZeneca said on Wednesday that the U.S. Food and Drug Administration had set a date of May 5, 2014 to act on the Epanova submission.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES